SOD1 and amyotrophic lateral sclerosis: In contrast to promising results in SOD1 mutation carriers, ASO therapy in C9ORF72 ALS (BIIB078) did not meet any secondary efficacy endpoints or demonstrate clinical benefit (NCT04288856), so the open label extension trial was stopped.